EU/3/13/1146: Orphan designation for the treatment of retinitis pigmentosa

unoprostone isopropyl


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in May 2016 on request of the Sponsor.

On 19 June 2013, orphan designation (EU/3/13/1146) was granted by the European Commission to Sucampo Pharma Europe Ltd, United Kingdom, for unoprostone isopropyl for the treatment of retinitis pigmentosa.

The sponsorship was transferred to Wainwright Associates Ltd, United Kingdom, in July 2015.

Key facts

Active substance
unoprostone isopropyl
Intended use
Treatment of retinitis pigmentosa
Orphan designation status
EU designation number
Date of designation
Wainwright Associates Ltd
Wessex House
Marlow Road
Bourne End
Buckinghamshire SL8 5SP
United Kingdom
Tel. +44 (0)1628 530 554
Fax +44 (0)1628 530 559

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating